What is (18F)Flutemetamol used for?

(18F)Flutemetamol is indicated for Amyloid Imaging.

Who makes (18F)Flutemetamol?

(18F)Flutemetamol is developed by Pfizer.

What development phase is (18F)Flutemetamol in?

(18F)Flutemetamol is FDA-approved (marketed).

What is the generic name of (18F)Flutemetamol?

18fflutemetamol is the generic (nonproprietary) name of (18F)Flutemetamol.

Last reviewed 2026-04-20 · How we verify

(18F)Flutemetamol (18fflutemetamol)

Pfizer · FDA-approved active Quality 22/100

(18F)Flutemetamol, marketed by Pfizer, is an amyloid imaging agent currently in use, competing directly with Florbetapir F 18, Florbetaben F 18, and another formulation of Flutemetamol F 18. A key strength is its established market presence, with a key composition patent expiring in 2028, providing some protection against generics. The primary risk lies in the competitive landscape, where multiple amyloid imaging agents are already marketed, potentially limiting revenue growth.

At a glance

Generic name	18fflutemetamol
Sponsor	Pfizer
Drug class	unknown
Target	unknown
Therapeutic area	Rare Disease
Phase	FDA-approved

Approved indications

Amyloid Imaging

Common side effects

No common side effects on file.

Drug interactions

Warfarin
Aspirin
Clopidogrel
Pentosan polysulfate
Dabigatran
Rivaroxaban
Apixaban
Edoxaban
Heparin
Low molecular weight heparin
Unfractionated heparin
Bivalirudin

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

(18F)Flutemetamol CI brief — competitive landscape report
(18F)Flutemetamol updates RSS · CI watch RSS
Pfizer portfolio CI